SS
KPTI icon

Steve Schonfeld’s Karyopharm Therapeutics KPTI Stock Holding History

Steve Schonfeld’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,333
Closed -$30K – 863
2018
Q1 		$30K Buy
+3,333
New +$665K ﹤0.01% 721

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Steve Schonfeld's KPTI Position: Q3 2024 in Review

Steve Schonfeld sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 3,840 shares — an estimated $50K sold.

Steve Schonfeld first reported a position in KPTI in Q1 2017 and held it in 17 quarters. The position peaked at $7.12M in Q3 2018. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Steve Schonfeld reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Steve Schonfeld sold 3,840 Karyopharm Therapeutics shares in Q3 2024, an estimated $50K.
  • Steve Schonfeld first reported a position in Karyopharm Therapeutics in Q1 2017 and held it in 17 quarters.
  • Steve Schonfeld's Karyopharm Therapeutics position peaked at $7.12M in Q3 2018.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.